Key terms

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ABBV news

Apr 08 3:50am ET Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), AbbVie (ABBV) and Immunome (IMNM) Apr 08 3:31am ET Analysts Conflicted on These Healthcare Names: AbbVie (ABBV), Universal Health (UHS) and Teladoc (TDOC) Apr 05 1:36am ET AbbVie (NYSE:ABBV) Trims EPS Outlook, Stock Drops Apr 03 7:27am ET Oppenheimer more bullish on Aldeyra, upgrades to Outperform Apr 03 5:20am ET Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV) and AbbVie (ABBV) Apr 02 11:16am ET AbbVie put volume heavy and directionally bearish Apr 01 5:58am ET This Biopharma Stock Outperformed MSTR and SMCI in March 2024 Mar 26 8:24pm ET AbbVie price target raised to $195 from $185 at Barclays Mar 25 9:10pm ET Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE) and AbbVie (ABBV) Mar 25 2:44pm ET Fly Insider: NextNav, Akamai among week’s notable insider trades Mar 25 8:35am ET AbbVie to acquire Landos Biopharma for $20.42 per share in cash plus CVR Mar 25 8:34am ET AbbVie to acquire Landos Biopharma got $20.42 per share in cash Mar 25 8:32am ET AbbVie to acquire Landos Biopharma for $20.42 per share in cash Mar 24 5:04am ET Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Legend Biotech (LEGN) Mar 24 5:03am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and Gilead Sciences (GILD) Mar 22 3:06pm ET AbbVie confirms FDA grants full approval for Elahere for certain ovarian cancers Mar 22 2:34pm ET FDA approves mirvetuximab soravtansine-gynx for certain cancers Mar 22 6:42am ET AbbVie price target raised to $190 from $188 at Guggenheim Mar 15 12:03pm ET JPMorgan biotech/pharma analysts hold an analyst/industry conference call Mar 12 8:40am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), AbbVie (ABBV) and ACADIA Pharmaceuticals (ACAD) Mar 05 8:08am ET Allergan Aesthetics announces FDA approval of JUVEDERM VOLUMA XC Mar 05 7:16am ET AbbVie makes milestone payment to Dragonfly after dosing in solid tumor trial Feb 28 6:06am ET AbbVie, OSE Immunotherapeutics enter pact to develop OSE-230 Feb 27 4:08pm ET Regenxbio expects cash to fund operations into 2H25 Feb 27 7:49am ET AbbVie’s epcoritamab granted priority review by FDA in follicular lymphoma Feb 27 7:48am ET Genmab, AbbVie announce FDA priority review for sBLA Feb 26 11:45am ET Truist biotech analysts hold an analyst/industry conference call Feb 26 4:55am ET Truist biotech analysts hold an analyst/industry conference call Feb 22 8:06am ET AbbVie, Tentarix announce multi-year collaboration Feb 21 5:39pm ET AbbVie targeting bond offering of at least $13B for M&A, Bloomberg says Feb 21 12:10pm ET Truist biotech analysts hold an analyst/industry conference call

No recent press releases are available for ABBV

ABBV Financials

1-year income & revenue

Key terms

ABBV Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ABBV Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms